1. Severity of depression and response to fluoxetine
- Author
-
Pande Ac and Sayler Me
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,medicine.drug_class ,medicine.medical_treatment ,Tricyclic antidepressant ,macromolecular substances ,Placebo ,Fluoxetine ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Psychiatry ,Depression (differential diagnoses) ,Aged ,Aged, 80 and over ,Psychiatric Status Rating Scales ,Clinical Trials as Topic ,Depressive Disorder ,Chemotherapy ,Middle Aged ,Clinical trial ,Psychiatry and Mental health ,Female ,Serotonin ,Psychology ,Reuptake inhibitor ,medicine.drug - Abstract
Pooled data from multiple, double-blind clinical trials comparing fluoxetine with either placebo, a tricyclic antidepressant (TCA) or both in patients with major depression were analyzed to assess the efficacy of these treatments in mild, moderate and severe depression. Fluoxetine-treated patients showed statistically significantly higher rates of response and remission than placebo-treated patients within all three severity subgroups. There were no differences in response or remission rates between fluoxetine and TCAs, regardless of symptom severity. Thus, the efficacy of fluoxetine was superior to placebo and similar to TCAs in mild, moderate and severe major depression.
- Published
- 1993